Pharmosa Biopharm Inc. (TPEX:6875)

Pharmosa Biopharm Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	845.76	749.44	974.06	672.51	461.46	414.54
Short-Term Investments	594	869	-	-	-	-
Cash & Short-Term Investments	1,440	1,618	974.06	672.51	461.46	414.54
Cash Growth	-22.82%	66.16%	44.84%	45.73%	11.32%	9672.18%
Accounts Receivable	-	4.65	-	-	-	-
Other Receivables	6.75	6.69	1.47	0.29	0.31	0.15
Receivables	6.75	11.34	1.47	0.29	0.31	0.15
Inventory	34.89	24.74	21.91	-	-	-
Prepaid Expenses	53.93	27.22	12.67	11.65	14.18	8.69
Other Current Assets	-	-	-	-	0.02	4
Total Current Assets	1,535	1,682	1,010	684.45	475.96	427.37
Property, Plant & Equipment	365.15	315.06	180.61	30.12	33.44	40.86
Long-Term Investments	72.58	73.26	71.22	65.69	61.6	60.91
Other Intangible Assets	0.61	0.66	0.09	0.15	0.18	-
Other Long-Term Assets	99.58	92.88	71.62	18.95	15.19	14.13
Total Assets	2,073	2,164	1,334	799.37	586.37	543.27
Accounts Payable	0.15	0.68	0.59	-	-	-
Accrued Expenses	-	61.51	33.24	12.28	11.66	10.43
Short-Term Debt	-	-	-	-	-	61
Current Portion of Long-Term Debt	-	-	1.26	3.52	8.43	18.81
Current Portion of Leases	18.14	17.98	24.69	7.19	6.8	6.43
Current Unearned Revenue	30.35	6.89	-	-	-	-
Other Current Liabilities	74.57	29.07	17.8	4.77	6.19	2.58
Total Current Liabilities	123.2	116.13	77.58	27.77	33.07	99.25
Long-Term Debt	-	-	1.19	2.45	5.96	14.83
Long-Term Leases	95.02	99.62	117.23	8.04	15.9	23.36
Long-Term Unearned Revenue	4.82	4.82	-	-	-	-
Other Long-Term Liabilities	5.14	5.1	-	-	-	-
Total Liabilities	228.19	225.66	195.99	38.25	54.93	137.44
Common Stock	645.43	645.43	586.02	554.67	489.24	402.5
Additional Paid-In Capital	1,439	1,439	531.34	1,180	-	454.19
Retained Earnings	-239.29	-146.37	20.28	-973.44	-706.94	-450.46
Comprehensive Income & Other	0.02	0.02	0.01	0.01	749.13	-0.41
Shareholders' Equity	1,845	1,938	1,138	761.12	531.44	405.83
Total Liabilities & Equity	2,073	2,164	1,334	799.37	586.37	543.27
Total Debt	113.16	117.6	144.37	21.19	37.09	124.43
Net Cash (Debt)	1,327	1,501	829.69	651.32	424.37	290.1
Net Cash Growth	-23.43%	80.89%	27.39%	53.48%	46.28%	-
Net Cash Per Share	10.26	11.87	7.32	6.61	5.00	6.09
Filing Date Shares Outstanding	129.06	129.09	117.2	110.93	97.85	49.99
Total Common Shares Outstanding	129.06	129.09	117.2	110.93	97.85	49.99
Working Capital	1,412	1,566	932.53	656.68	442.89	328.12
Book Value Per Share	14.30	15.01	9.71	6.86	5.43	8.12
Tangible Book Value	1,844	1,937	1,138	760.97	531.25	405.83
Tangible Book Value Per Share	14.29	15.01	9.71	6.86	5.43	8.12
Machinery	-	68.34	27.11	26.37	17.05	19.59
Construction In Progress	-	134.42	-	-	-	-
Leasehold Improvements	-	28.85	35.61	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.